论文部分内容阅读
目的 分析孟鲁司特钠+布地奈德治疗支气管哮喘的应用价值及临床疗效。方法 择取本院在2017年8月至2018年8月所收治的80例支气管哮喘患者进行研究，根据中心分组方式将患者归为试验组（n=40）与参照组（n=40）。参照组实施布地奈德治疗，试验组实施孟鲁司特钠片联合布地奈德治疗，对比两组患者的临床疗效、治疗前后免疫球功能变化、肺功能改善情况及不良反应发生率。结果 试验组总有效率为95.00%明显高于参照组的77.50%，P＜0.05；两组干预前CD_3^+、CD_4^+、CD_8^+指标对比未见差异（P＞“,”Objective To analyze the application value and clinical efficacy of montelukast sodium+budesonide in the treatment of bronchial asthma.Methods Eighty patients with bronchial asthma admitted to our hospital from August 2017 to August 2018 were enrolled. The patients were classified into the experimental group (n=40 cases) and the reference group (n=40) according to the central grouping method. The reference group was treated with budesonide. The experimental group was treated with montelukast sodium tablets combined with budesonide. The clinical efficacy， immunoglobulin function，lung function improvement and adverse reaction rate were compared between the two groups. Results The total effective rate of the experimental group was 95.00% higher than that of the reference group (77.50%)， P＜0.05. There was no difference in CD_3^+， CD_4^+， CD8+ index comparison between the two groups before intervention (P＞0.05)， after treatment， the CD_3^+andCD_4^+levels in the reference group and the experimental group were higher than before treatment， and the CD8+ level was lower than before treatment. The test group CD_3^+， CD_4^+ level was higher than the reference group， and the CD_8^+ level was lower than the reference group， P＜0.05. There was no difference in the index of forced expiratory volume and forced vital capacity in the first second before the intervention between the two groups (P＞0.05)， the forced expiratory volume and forced vital capacity in the first second of the experimental group were higher than the reference group， P＜0.05; there was no difference in the comparison of TNF-α， IL-6 and IL-8 indexes between the two groups before intervention (P＞0.05); after intervention， the index values of the experimental group were lower than those of the reference group， P＜0.05; the MAP index of the experimental group was compared with that before administration. 1 day after administration， compared with the reference group， there was no difference， P＞0.05， the HR index before administration was compared with the reference group， there was no difference， P＞0.05; in the rest of the time period， the test group index was better than the reference group， (P＜0.05). The incidence of adverse reactions in the two groups was compared， P＞0.05.Conclusion Compared with budesonide alone， the combination of montelukast sodium and budesonide in the treatment of bronchial asthma can improve the body\'s immunity， strengthen lung function and reduce the incidence of adverse reactions. The clinical effect is clear.